Summary
Global Markets Direct’s, ‘Crohn’s Disease (Regional Enteritis) - Pipeline Review, H1 2016’, provides an overview of the Crohn’s Disease (Regional Enteritis) pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Crohn’s Disease (Regional Enteritis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Crohn’s Disease (Regional Enteritis) and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Crohn’s Disease (Regional Enteritis)
- The report reviews pipeline therapeutics for Crohn’s Disease (Regional Enteritis) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Crohn’s Disease (Regional Enteritis) therapeutics and enlists all their major and minor projects
- The report assesses Crohn’s Disease (Regional Enteritis) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Crohn’s Disease (Regional Enteritis)
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Crohn’s Disease (Regional Enteritis)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Crohn’s Disease (Regional Enteritis) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
4D Pharma Plc
4SC AG
AB Science SA
AbbVie Inc.
Alfa Wassermann S.p.A
Amgen Inc.
Ampio Pharmaceuticals, Inc.
Arena Pharmaceuticals, Inc.
Avaxia Biologics, Inc.
BioAtla, LLC
BIOCAD
BioLingus AG
Bionovis SA
BioTherapeutics Inc.
Boehringer Ingelheim GmbH
Calypso Biotech SA
Celgene Corporation
Celltrion, Inc.
ChemoCentryx, Inc.
ChironWells GmbH
Chong Kun Dang Pharmaceutical Corp.
CLL Pharma
Commence Bio, Inc.
Daiichi Sankyo Company, Limited
DBV Technologies S.A.
Effimune SAS
Eisai Co., Ltd.
Eli Lilly and Company
Enterome Bioscience SA
Enzo Biochem, Inc.
Epirus Biopharmaceuticals, Inc.
Ferring International Center S.A.
Galapagos NV
Genentech, Inc.
Genfit SA
Genor BioPharma Co., Ltd.
Gilead Sciences, Inc.
Idera Pharmaceuticals, Inc.
Immune Response BioPharma, Inc.
Inbiopro Solutions Pvt. Ltd.
Innovate Biopharmaceuticals, Inc.
Innovent Biologics, Inc.
Johnson & Johnson
Jyant Technologies, Inc.
Kineta, Inc.
Kymab Limited
Kyorin Pharmaceutical Co., Ltd.
Mabion SA
MedImmune, LLC
Mesoblast Limited
Mitsubishi Tanabe Pharma Corporation
Momenta Pharmaceuticals, Inc.
Mycenax Biotech Inc.
Neovacs SA
Ocata Therapeutics, Inc.
Oncobiologics, Inc.
Oncodesign SA
Pfenex Inc.
Pfizer Inc.
Pluristem Therapeutics Inc.
Protagonist Therapeutics Inc.
Protalix BioTherapeutics, Inc.
Qu Biologics Inc.
Re-Pharm Limited
Receptos, Inc.
RedHill Biopharma Ltd.
SATT Nord
Selexys Pharmaceuticals Corporation
Sigmoid Pharma Limited
Soligenix, Inc.
Stelic Institute & Co., Inc.
Sylentis S.A.U.
TaiwanJ Pharmaceuticals Co., Ltd.
Takeda Pharmaceutical Company Limited
Therapeutic Proteins International, LLC
Tiziana Life Sciences PLC
Toray Industries, Inc.
Trino Therapeutics Limited
TxCell SA
Ventria Bioscience
Virobay Inc.
Xbrane Biopharma AB
'
Table of Contents
Table of Contents 2
Introduction 7
Crohn’s Disease (Regional Enteritis) Overview 8
Therapeutics Development 9
Crohn’s Disease (Regional Enteritis) - Therapeutics under Development by Companies 11
Crohn’s Disease (Regional Enteritis) - Therapeutics under Investigation by Universities/Institutes 19
Crohn’s Disease (Regional Enteritis) - Pipeline Products Glance 20
Crohn’s Disease (Regional Enteritis) - Products under Development by Companies 24
Crohn’s Disease (Regional Enteritis) - Products under Investigation by Universities/Institutes 33
Crohn’s Disease (Regional Enteritis) - Companies Involved in Therapeutics Development 34
Crohn’s Disease (Regional Enteritis) - Therapeutics Assessment 116
Drug Profiles 133
Crohn’s Disease (Regional Enteritis) - Recent Pipeline Updates 327
Crohn’s Disease (Regional Enteritis) - Dormant Projects 436
Crohn’s Disease (Regional Enteritis) - Discontinued Products 447
Crohn’s Disease (Regional Enteritis) - Product Development Milestones 449
Appendix 456
List of Tables
Number of Products under Development for Crohn’s Disease (Regional Enteritis), H1 2016 24
Number of Products under Development for Crohn’s Disease (Regional Enteritis) - Comparative Analysis, H1 2016 25
Number of Products under Development by Companies, H1 2016 27
Number of Products under Development by Companies, H1 2016 (Contd..1) 28
Number of Products under Development by Companies, H1 2016 (Contd..2) 29
Number of Products under Development by Companies, H1 2016 (Contd..3) 30
Number of Products under Development by Companies, H1 2016 (Contd..4) 31
Number of Products under Development by Companies, H1 2016 (Contd..5) 32
Number of Products under Development by Companies, H1 2016 (Contd..6) 33
Number of Products under Investigation by Universities/Institutes, H1 2016 34
Comparative Analysis by Late Stage Development, H1 2016 35
Comparative Analysis by Clinical Stage Development, H1 2016 36
Comparative Analysis by Early Stage Development, H1 2016 37
Comparative Analysis by Unknown Stage Development, H1 2016 38
Products under Development by Companies, H1 2016 39
Products under Development by Companies, H1 2016 (Contd..1) 40
Products under Development by Companies, H1 2016 (Contd..2) 41
Products under Development by Companies, H1 2016 (Contd..3) 42
Products under Development by Companies, H1 2016 (Contd..4) 43
Products under Development by Companies, H1 2016 (Contd..5) 44
Products under Development by Companies, H1 2016 (Contd..6) 45
Products under Development by Companies, H1 2016 (Contd..7) 46
Products under Development by Companies, H1 2016 (Contd..8) 47
Products under Investigation by Universities/Institutes, H1 2016 48
Crohn’s Disease (Regional Enteritis) - Pipeline by 4D Pharma Plc, H1 2016 49
Crohn’s Disease (Regional Enteritis) - Pipeline by 4SC AG, H1 2016 50
Crohn’s Disease (Regional Enteritis) - Pipeline by AB Science SA, H1 2016 51
Crohn’s Disease (Regional Enteritis) - Pipeline by AbbVie Inc., H1 2016 52
Crohn’s Disease (Regional Enteritis) - Pipeline by Alfa Wassermann S.p.A, H1 2016 53
Crohn’s Disease (Regional Enteritis) - Pipeline by Amgen Inc., H1 2016 54
Crohn’s Disease (Regional Enteritis) - Pipeline by Ampio Pharmaceuticals, Inc., H1 2016 55
Crohn’s Disease (Regional Enteritis) - Pipeline by Arena Pharmaceuticals, Inc., H1 2016 56
Crohn’s Disease (Regional Enteritis) - Pipeline by Avaxia Biologics, Inc., H1 2016 57
Crohn’s Disease (Regional Enteritis) - Pipeline by BioAtla, LLC, H1 2016 58
Crohn’s Disease (Regional Enteritis) - Pipeline by BIOCAD, H1 2016 59
Crohn’s Disease (Regional Enteritis) - Pipeline by BioLingus AG, H1 2016 60
Crohn’s Disease (Regional Enteritis) - Pipeline by Bionovis SA, H1 2016 61
Crohn’s Disease (Regional Enteritis) - Pipeline by BioTherapeutics Inc., H1 2016 62
Crohn’s Disease (Regional Enteritis) - Pipeline by Boehringer Ingelheim GmbH, H1 2016 63
Crohn’s Disease (Regional Enteritis) - Pipeline by Calypso Biotech SA, H1 2016 64
Crohn’s Disease (Regional Enteritis) - Pipeline by Celgene Corporation, H1 2016 65
Crohn’s Disease (Regional Enteritis) - Pipeline by Celltrion, Inc., H1 2016 66
Crohn’s Disease (Regional Enteritis) - Pipeline by ChemoCentryx, Inc., H1 2016 67
Crohn’s Disease (Regional Enteritis) - Pipeline by ChironWells GmbH, H1 2016 68
Crohn’s Disease (Regional Enteritis) - Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2016 69
Crohn’s Disease (Regional Enteritis) - Pipeline by CLL Pharma, H1 2016 70
Crohn’s Disease (Regional Enteritis) - Pipeline by Commence Bio, Inc., H1 2016 71
Crohn’s Disease (Regional Enteritis) - Pipeline by Daiichi Sankyo Company, Limited, H1 2016 72
Crohn’s Disease (Regional Enteritis) - Pipeline by DBV Technologies S.A., H1 2016 73
Crohn’s Disease (Regional Enteritis) - Pipeline by Effimune SAS, H1 2016 74
Crohn’s Disease (Regional Enteritis) - Pipeline by Eisai Co., Ltd., H1 2016 75
Crohn’s Disease (Regional Enteritis) - Pipeline by Eli Lilly and Company, H1 2016 76
Crohn’s Disease (Regional Enteritis) - Pipeline by Enterome Bioscience SA, H1 2016 77
Crohn’s Disease (Regional Enteritis) - Pipeline by Enzo Biochem, Inc., H1 2016 78
Crohn’s Disease (Regional Enteritis) - Pipeline by Epirus Biopharmaceuticals, Inc., H1 2016 79
Crohn’s Disease (Regional Enteritis) - Pipeline by Ferring International Center S.A., H1 2016 80
Crohn’s Disease (Regional Enteritis) - Pipeline by Galapagos NV, H1 2016 81
Crohn’s Disease (Regional Enteritis) - Pipeline by Genentech, Inc., H1 2016 82
Crohn’s Disease (Regional Enteritis) - Pipeline by Genfit SA, H1 2016 83
Crohn’s Disease (Regional Enteritis) - Pipeline by Genor BioPharma Co., Ltd., H1 2016 84
Crohn’s Disease (Regional Enteritis) - Pipeline by Gilead Sciences, Inc., H1 2016 85
Crohn’s Disease (Regional Enteritis) - Pipeline by Idera Pharmaceuticals, Inc., H1 2016 86
Crohn’s Disease (Regional Enteritis) - Pipeline by Immune Response BioPharma, Inc., H1 2016 87
Crohn’s Disease (Regional Enteritis) - Pipeline by Inbiopro Solutions Pvt. Ltd., H1 2016 88
Crohn’s Disease (Regional Enteritis) - Pipeline by Innovate Biopharmaceuticals, Inc., H1 2016 89
Crohn’s Disease (Regional Enteritis) - Pipeline by Innovent Biologics, Inc., H1 2016 90
Crohn’s Disease (Regional Enteritis) - Pipeline by Johnson & Johnson, H1 2016 91
Crohn’s Disease (Regional Enteritis) - Pipeline by Jyant Technologies, Inc., H1 2016 92
Crohn’s Disease (Regional Enteritis) - Pipeline by Kineta, Inc., H1 2016 93
Crohn’s Disease (Regional Enteritis) - Pipeline by Kymab Limited, H1 2016 94
Crohn’s Disease (Regional Enteritis) - Pipeline by Kyorin Pharmaceutical Co., Ltd., H1 2016 95
Crohn’s Disease (Regional Enteritis) - Pipeline by Mabion SA, H1 2016 96
Crohn’s Disease (Regional Enteritis) - Pipeline by MedImmune, LLC, H1 2016 97
Crohn’s Disease (Regional Enteritis) - Pipeline by Mesoblast Limited, H1 2016 98
Crohn’s Disease (Regional Enteritis) - Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2016 99
Crohn’s Disease (Regional Enteritis) - Pipeline by Momenta Pharmaceuticals, Inc., H1 2016 100
Crohn’s Disease (Regional Enteritis) - Pipeline by Mycenax Biotech Inc., H1 2016 101
Crohn’s Disease (Regional Enteritis) - Pipeline by Neovacs SA, H1 2016 102
Crohn’s Disease (Regional Enteritis) - Pipeline by Ocata Therapeutics, Inc., H1 2016 103
Crohn’s Disease (Regional Enteritis) - Pipeline by Oncobiologics, Inc., H1 2016 104
Crohn’s Disease (Regional Enteritis) - Pipeline by Oncodesign SA, H1 2016 105
Crohn’s Disease (Regional Enteritis) - Pipeline by Pfenex Inc., H1 2016 106
Crohn’s Disease (Regional Enteritis) - Pipeline by Pfizer Inc., H1 2016 107
Crohn’s Disease (Regional Enteritis) - Pipeline by Pluristem Therapeutics Inc., H1 2016 108
Crohn’s Disease (Regional Enteritis) - Pipeline by Protagonist Therapeutics Inc., H1 2016 109
Crohn’s Disease (Regional Enteritis) - Pipeline by Protalix BioTherapeutics, Inc., H1 2016 110
Crohn’s Disease (Regional Enteritis) - Pipeline by Qu Biologics Inc., H1 2016 111
Crohn’s Disease (Regional Enteritis) - Pipeline by Re-Pharm Limited, H1 2016 112
Crohn’s Disease (Regional Enteritis) - Pipeline by Receptos, Inc., H1 2016 113
Crohn’s Disease (Regional Enteritis) - Pipeline by RedHill Biopharma Ltd., H1 2016 114
Crohn’s Disease (Regional Enteritis) - Pipeline by SATT Nord, H1 2016 115
Crohn’s Disease (Regional Enteritis) - Pipeline by Selexys Pharmaceuticals Corporation, H1 2016 116
Crohn’s Disease (Regional Enteritis) - Pipeline by Sigmoid Pharma Limited, H1 2016 117
Crohn’s Disease (Regional Enteritis) - Pipeline by Soligenix, Inc., H1 2016 118
Crohn’s Disease (Regional Enteritis) - Pipeline by Stelic Institute & Co., Inc., H1 2016 119
Crohn’s Disease (Regional Enteritis) - Pipeline by Sylentis S.A.U., H1 2016 120
Crohn’s Disease (Regional Enteritis) - Pipeline by TaiwanJ Pharmaceuticals Co., Ltd., H1 2016 121
Crohn’s Disease (Regional Enteritis) - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 122
Crohn’s Disease (Regional Enteritis) - Pipeline by Therapeutic Proteins International, LLC, H1 2016 123
Crohn’s Disease (Regional Enteritis) - Pipeline by Tiziana Life Sciences PLC, H1 2016 124
Crohn’s Disease (Regional Enteritis) - Pipeline by Toray Industries, Inc., H1 2016 125
Crohn’s Disease (Regional Enteritis) - Pipeline by Trino Therapeutics Limited, H1 2016 126
Crohn’s Disease (Regional Enteritis) - Pipeline by TxCell SA, H1 2016 127
Crohn’s Disease (Regional Enteritis) - Pipeline by Ventria Bioscience, H1 2016 128
Crohn’s Disease (Regional Enteritis) - Pipeline by Virobay Inc., H1 2016 129
Crohn’s Disease (Regional Enteritis) - Pipeline by Xbrane Biopharma AB, H1 2016 130
Assessment by Monotherapy Products, H1 2016 131
Assessment by Combination Products, H1 2016 132
Number of Products by Stage and Target, H1 2016 134
Number of Products by Stage and Mechanism of Action, H1 2016 140
Number of Products by Stage and Route of Administration, H1 2016 145
Number of Products by Stage and Molecule Type, H1 2016 147
Crohn’s Disease (Regional Enteritis) Therapeutics - Recent Pipeline Updates, H1 2016 342
Crohn’s Disease (Regional Enteritis) - Dormant Projects, H1 2016 451
Crohn’s Disease (Regional Enteritis) - Dormant Projects (Contd..1), H1 2016 452
Crohn’s Disease (Regional Enteritis) - Dormant Projects (Contd..2), H1 2016 453
Crohn’s Disease (Regional Enteritis) - Dormant Projects (Contd..3), H1 2016 454
Crohn’s Disease (Regional Enteritis) - Dormant Projects (Contd..4), H1 2016 455
Crohn’s Disease (Regional Enteritis) - Dormant Projects (Contd..5), H1 2016 456
Crohn’s Disease (Regional Enteritis) - Dormant Projects (Contd..6), H1 2016 457
Crohn’s Disease (Regional Enteritis) - Dormant Projects (Contd..7), H1 2016 458
Crohn’s Disease (Regional Enteritis) - Dormant Projects (Contd..8), H1 2016 459
Crohn’s Disease (Regional Enteritis) - Dormant Projects (Contd..9), H1 2016 460
Crohn’s Disease (Regional Enteritis) - Dormant Projects (Contd..10), H1 2016 461
Crohn’s Disease (Regional Enteritis) - Discontinued Products, H1 2016 462
Crohn’s Disease (Regional Enteritis) - Discontinued Products (Contd..1), H1 2016 463
List of Figures
Number of Products under Development for Crohn’s Disease (Regional Enteritis), H1 2016 24
Number of Products under Development for Crohn’s Disease (Regional Enteritis) - Comparative Analysis, H1 2016 25
Number of Products under Development by Companies, H1 2016 26
Number of Products under Investigation by Universities/Institutes, H1 2016 34
Comparative Analysis by Late Stage Development, H1 2016 35
Comparative Analysis by Clinical Stage Development, H1 2016 36
Comparative Analysis by Early Stage Products, H1 2016 37
Assessment by Monotherapy Products, H1 2016 131
Number of Products by Top 10 Targets, H1 2016 133
Number of Products by Stage and Top 10 Targets, H1 2016 133
Number of Products by Top 10 Mechanism of Actions, H1 2016 139
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 139
Number of Products by Top 10 Routes of Administration, H1 2016 144
Number of Products by Stage and Top 10 Routes of Administration, H1 2016 144
Number of Products by Top 10 Molecule Types, H1 2016 146
Number of Products by Stage and Top 10 Molecule Types, H1 2016 146
